Athersys Stock Forecast, Price & News

+0.01 (+0.62 %)
(As of 06/11/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume690,927 shs
Average Volume2.59 million shs
Market Capitalization$362.00 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ATHX News and Ratings via Email

Sign-up to receive the latest news and ratings for Athersys and its competitors with MarketBeat's FREE daily newsletter.

Athersys logo

About Athersys

Athersys, Inc., a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. Its clinical development programs are focused on treating neurological conditions, cardiovascular diseases, inflammatory and immune disorders, and pulmonary and other conditions. The company's lead platform product includes MultiStem cell therapy, an allogeneic stem cell product, which is in Phase III clinical study for the treatment of patients suffering from neurological damage from an ischemic stroke, as well as in Phase II clinical study for the treatment of patients with acute myocardial infarction, and has completed Phase I clinical study for the treatment of patients suffering from leukemia or various other blood-borne cancers. It also develops MultiStem cell therapy to promote tissue repair and healing for animal patients, including those suffering from serious conditions with unmet medical needs. The company has license and collaboration agreements with Healios K.K. to develop and commercialize MultiStem cell therapy for ischemic stroke, acute respiratory distress syndrome, and ophthalmological indications, as well as for the treatment of liver, kidney, pancreas, and intestinal tissue diseases; and the University of Minnesota to develop MultiStem cell therapy platform. Athersys, Inc. was founded in 1995 and is headquartered in Cleveland, Ohio.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.35 out of 5 stars

Medical Sector

813th out of 2,096 stocks

Pharmaceutical Preparations Industry

396th out of 830 stocks

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Athersys (NASDAQ:ATHX) Frequently Asked Questions

Is Athersys a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Athersys in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Athersys stock.
View analyst ratings for Athersys
or view top-rated stocks.

What stocks does MarketBeat like better than Athersys?

Wall Street analysts have given Athersys a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Athersys wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Athersys' next earnings date?

Athersys is scheduled to release its next quarterly earnings announcement on Monday, August 9th 2021.
View our earnings forecast for Athersys

How were Athersys' earnings last quarter?

Athersys, Inc. (NASDAQ:ATHX) released its quarterly earnings data on Wednesday, May, 5th. The biopharmaceutical company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by $0.05.
View Athersys' earnings history

How has Athersys' stock been impacted by Coronavirus?

Athersys' stock was trading at $1.28 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ATHX shares have increased by 27.3% and is now trading at $1.63.
View which stocks have been most impacted by COVID-19

What price target have analysts set for ATHX?

3 brokerages have issued 12 month price targets for Athersys' stock. Their forecasts range from $5.00 to $5.00. On average, they expect Athersys' stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 206.7% from the stock's current price.
View analysts' price targets for Athersys
or view top-rated stocks among Wall Street analysts.

Who are Athersys' key executives?

Athersys' management team includes the following people:
  • Mr. William B. J. Lehmann Jr., M.B.A., J.D., MBA, Pres, COO, Sec. & Interim CEO (Age 55, Pay $533.6k)
  • Dr. John J. Harrington, Co-Founder, Chief Scientific Officer, Exec. VP & Director (Age 54, Pay $534.86k)
  • Mr. Ivor Macleod CPA, M.B.A., Chief Financial Officer (Age 59, Pay $587.21k)
  • Ms. Laura K. Campbell CPA, CPA, Sr. VP of Fin. (Age 57, Pay $371.36k)
  • Ms. Karen Hunady M.S., Director of Corp. Communications & Investor Relations
  • Ms. Alison O'Sullivan M.B.A., Sr. Director of HR
  • Dr. Manal Morsy M.D., PH.D., Sr. VP & Head of Global Regulatory Affairs
  • Dr. Robert Mays, VP of Regenerative Medicine & Head of Neuroscience Programs
  • Mr. Rakesh Ramachandran, Head of Information Technology & Communications and VP
  • Mr. Gregory F. Liposky M.B.A., Sr. VP Commercial Manufacturing (Age 66)

What is Gil Van Bokkelen's approval rating as Athersys' CEO?

2 employees have rated Athersys CEO Gil Van Bokkelen on Gil Van Bokkelen has an approval rating of 100% among Athersys' employees. This puts Gil Van Bokkelen in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Athersys' key competitors?

What other stocks do shareholders of Athersys own?

What is Athersys' stock symbol?

Athersys trades on the NASDAQ under the ticker symbol "ATHX."

Who are Athersys' major shareholders?

Athersys' stock is owned by a number of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.40%), JPMorgan Chase & Co. (1.53%), Geode Capital Management LLC (1.38%), Northern Trust Corp (0.87%), Citigroup Inc. (0.34%) and Bank of New York Mellon Corp (0.32%). Company insiders that own Athersys stock include John J Harrington, Kenneth H Traub, Laura K Campbell and William Lehmann Jr.
View institutional ownership trends for Athersys

Which major investors are selling Athersys stock?

ATHX stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Russell Investments Group Ltd., Morgan Stanley, Northern Trust Corp, Goldman Sachs Group Inc., Alliancebernstein L.P., AQR Capital Management LLC, and Nuveen Asset Management LLC. Company insiders that have sold Athersys company stock in the last year include John J Harrington, Laura K Campbell, and William Lehmann Jr.
View insider buying and selling activity for Athersys
or view top insider-selling stocks.

Which major investors are buying Athersys stock?

ATHX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., UBS Group AG, Citigroup Inc., Rafferty Asset Management LLC, Geode Capital Management LLC, BlackRock Inc., Squarepoint Ops LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Athersys
or or view top insider-buying stocks.

How do I buy shares of Athersys?

Shares of ATHX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Athersys' stock price today?

One share of ATHX stock can currently be purchased for approximately $1.63.

How much money does Athersys make?

Athersys has a market capitalization of $362.00 million and generates $1.44 million in revenue each year. The biopharmaceutical company earns $-78,760,000.00 in net income (profit) each year or ($0.42) on an earnings per share basis.

How many employees does Athersys have?

Athersys employs 97 workers across the globe.

What is Athersys' official website?

The official website for Athersys is

Where are Athersys' headquarters?

Athersys is headquartered at 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115.

How can I contact Athersys?

Athersys' mailing address is 3201 CARNEGIE AVENUE, CLEVELAND OH, 44115. The biopharmaceutical company can be reached via phone at 216-431-9900 or via email at [email protected]

This page was last updated on 6/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.